AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
HCW BIOLOGICS INC.
(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)
HCW BIOLOGICS INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”),
DOES HEREBY CERTIFY:
1. That the name of this corporation is HCW BIOLOGICS INC., and that this corporation was originally incorporated pursuant to the General Corporation Law pursuant to a Certificate of Incorporation filed with the Secretary of State of the State of Delaware on April 2, 2018 under the name HCW BIOLOGICS INC., and subsequently such Certificate of Incorporation was amended on April 6, 2018, November 15, 2018, and June 6, 2019.
2. That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:
RESOLVED, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:
FIRST: The name of this corporation is HCW BIOLOGICS INC. (the “Corporation”).
SECOND: The address of the registered office of the Corporation in the State of Delaware is 251 Littlefalls Drive, in the City of Wilmington, 19808, County of Newcastle. The name of its registered agent at such address is Corporation Service Company.
THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.
FOURTH: The total number of shares of all classes of stock that the Corporation will have authority to issue is (i) 84,950,215 shares of Common Stock, $0.0001 par value per share (“Common Stock”), 74,950,215 of which shares shall be designated “Class A Common Stock” and 10,000,000 of which shares shall be designated “Class B Common Stock” and (ii) 60,950,215 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”), 14,738,948 of which shares shall be designated “Series A Preferred Stock”, 28,029,449 of which shares shall be designated “Series B Preferred Stock”, and 18,181,818 of which shares shall be designated “Series C Preferred Stock”. For purposes herein, references to Common Stock hereunder shall refer to Class A Common Stock and/or Class B Common Stock, as applicable, and references to Preferred Stock shall refer to Series A Preferred Stock, Series B Preferred Stock, and/or Series C Preferred Stock, as applicable.
1.